Effect of cholesterol lowering on progression of aortic stenosis in patients with mild to moderate aortic stenosis: a randomised controlled trial

niversity of Ottawa (Canada)0 个研究点目标入组 264 人开始时间: 2005年9月5日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Age 18 to 82 years
•2. Both men and women will be included
•3. At least mild AS defined by peak Doppler aortic valve velocity = 2.5 m/sec
•4. Moderate risk for coronary artery disease (CAD), with low density lipoprotein cholesterol (LDL-C) less than 4 mmol/l and total cholesterol: high density lipoprotein cholesterol (HDL-C) ratio less than 6
•5. Low risk for CAD with LDL-C less than 5 mmol/l and total cholesterol: HDL-C less than 7

•1. Peak Doppler aortic valve velocity less than 2.5 m/sec, because of the rate of progression in these patients is not well defined
•2. Severe AS (a mean aortic gradient = 40 mmHg or AVA = 0.9 cm^2). These patients are excluded because they will have a high probability of aortic valve replacement even without further AS progression.
•3. Symptomatic AS
•4. Greater than moderate aortic regurgitation
•5. Patients with significant concomitant mitral valve disease, defined by greater than moderate MR or MVA less than 2.0 cm^2
•6. Patients on cholesterol lowering agents
•7. Symptomatic coronary artery disease
•8. Diabetes mellitus either on oral agent or insulin
•9. At high or very high risks for CAD (10 year risk greater than 20%)
•10. Moderate risk for CAD, but LDL-C greater than 4 mmol/l or total cholesterol: HDL-C ratio greater than 6
•11. Low risk for CAD, but LDL-C greater than 5 mmol/l or total cholesterol: HDL-C ratio greater than 7
•12. Pregnant or lactating women
•13. Inability to return for follow up visits
•14. Concomitant medical conditions, which limit the survival in the next 5 years
•15. Inability or unwillingness to provide informed consent

发起方

niversity of Ottawa (Canada)